Oxytocin Research, Specifications & Scientific Information

Introduction

Oxytocin has two literatures and they do not resemble each other.

The first is obstetric, a century old, and about as settled as clinical pharmacology gets: an injectable hormone that acts on the myometrium, given by clinicians to initiate or improve uterine contractions and to control bleeding after delivery, supported by evidence down to the level of individual participant data meta-analysis ^[9]. That is what the approved products are for.

The second is behavioural, thirty years old, and unresolved. It concerns intranasal administration and whether it changes social cognition, and it has produced a very large number of small positive studies, one large phase 3 trial in autism that found no benefit ^[2], meta-analyses that reach guarded conclusions ^{[6, 7]}, and a standing objection from neuroendocrinologists that the delivery route may not do what the field assumes ^[4].

This page keeps them apart. Almost everything asserted about oxytocin in general circulation comes from the second literature and is stated with a confidence the first literature has earned and the second has not.

What Is Oxytocin?

Oxytocin is a cyclic nonapeptide hormone: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, with a disulphide bond between the cysteines at positions 1 and 6 closing a six-residue ring, and a three-residue tail ending in an amide.

It is synthesised in magnocellular neurons of the hypothalamus and released into the circulation from the posterior pituitary. It is also released within the brain, from the same neurons' central projections — a distinction that matters a great deal to the behavioural literature, because peripheral and central oxytocin are not one pool.

Its close relative vasopressin differs from it at two positions only. That similarity is not a curiosity: oxytocin has appreciable activity at the vasopressin V1a receptor as well as at its own ^[1], so an effect observed after giving oxytocin is not automatically an effect of oxytocin receptor activation.

PubChem holds it under compound identifier 439302, with CAS registry number 50-56-6 and FDA/NCATS UNII code 1JQS135EYN.

Approved injectable products containing it exist in the United States for obstetric use. No intranasal oxytocin product is approved in the United States, or anywhere, for a psychiatric or behavioural indication.

Oxytocin Specifications

Oxytocin is a cyclic nonapeptide: a six-residue ring closed by a disulphide bond between the cysteines at positions 1 and 6, with a three-residue tail ending in a C-terminal amide. It was among the first peptide hormones to have its structure determined and to be synthesised chemically, work that established the field of peptide synthesis. It differs from vasopressin, its neurohypophysial partner, at only two positions, which is why cross-reactivity at the vasopressin receptors is a real pharmacological consideration rather than a theoretical one. PubChem carries it under compound identifier 439302, with CAS registry number 50-56-6 and the FDA/NCATS UNII code 1JQS135EYN; an acetate salt form carries its own UNII, 4NR672T8NL. The disulphide bond is the molecule's principal stability liability: reduction opens the ring and abolishes activity, and the linear reduced form differs from the intact peptide by only two daltons.

Values that a public register does not carry are shown as not publicly characterised rather than estimated. Identifiers are reference values; the certificate of analysis supplied with a laboratory order is the record for a given lot.

How Does Oxytocin Work?

The receptor is the oxytocin receptor, a Gq/11-coupled class A G protein-coupled receptor whose structure, signalling and regulation are set out in the standard review of the system ^[1]. Activation raises intracellular calcium.

Peripherally, the account is complete and uncontroversial. Oxytocin receptors in the myometrium mediate uterine contraction, and their expression rises sharply near term — one reason the same hormone has little effect earlier in pregnancy and a large one at delivery. Receptors in mammary tissue mediate the milk-ejection reflex. This is the pharmacology the approved products rest on.

Centrally, three separate questions are often run together, and separating them is the most useful thing this page can do.

1. Are there central oxytocin receptors, and does endogenous oxytocin act on them? Yes. Receptor expression in the central nervous system is established, and so is central release from hypothalamic projections ^[1].
2. Does administered oxytocin reach those receptors? This is the disputed question. A 2016 critique argued that the pharmacological assumptions behind intranasal administration are not supported by the evidence ^[4], and rodent work applying the closely related peptide vasopressin intranasally found no detectable change in brain immediate early gene expression, in neural activity, or in behaviour ^[5].
3. If it arrives, does it change behaviour? The trials address this, and the largest of them was negative ^[2].

A programme in which question two is open makes question three hard to interpret in either direction. A negative trial might mean the hormone does not produce the effect, or that it never reached the receptors. A positive one carries the same ambiguity in reverse.

Oxytocin Mechanism of Action

In vitro research

The receptor system. Structure, function, tissue distribution and regulation of the oxytocin receptor are characterised in detail, including the marked upregulation of myometrial receptor expression toward term that gives the hormone its obstetric utility, and the cross-reactivity with vasopressin receptors that complicates attribution of any observed effect ^[1].

What this establishes and what it does not. Receptor-level characterisation establishes that the molecule has a defined target with a defined signalling mechanism in defined tissues. It does not establish that a given route of administration delivers the molecule to any particular one of those tissues, which is the separate question the behavioural literature turns on.

Findings in this section were obtained in receptor and tissue systems. Nothing in them establishes anything about intact animals or about humans.

What Is Oxytocin Being Researched For?

• Obstetric care — prevention and management of postpartum haemorrhage, where prophylactic administration after delivery is standard international practice and has been examined at the level of individual participant data ^[9].
• Autism spectrum disorder — intranasal administration for social behaviour, the largest single investigational programme, including the phase 3 SOARS-B trial ^{[2, 3]} and continuing work on imaging and biological correlates.
• Psychiatric conditions more broadly — pooled across disorders in meta-analysis ^[6].
• The methodology of its own trials — placebo response in autism trials has become a research subject in its own right, studied directly through placebo lead-in phases ^[8].
• The delivery route — whether intranasal administration reaches central receptors at all ^{[4, 5]}.

The obstetric work concerns a licensed pharmaceutical product administered by clinicians. The behavioural work is investigational. Neither is research into, or evidence about, research-grade material supplied for laboratory use.

Human Research on Oxytocin

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

SOARS-B: intranasal oxytocin in autism spectrum disorder, 2021

Design. A phase 3 randomised placebo-controlled trial of intranasal oxytocin in children and adolescents with autism spectrum disorder, conducted through the Autism Centers of Excellence network, with social behaviour as the primary outcome ^{[2, 3]}.

Result. The trial did not show a significant difference from placebo on its primary outcome ^[2].

Why this trial carries more weight than the literature preceding it. It was designed prospectively with its rationale and methods published in advance ^[3], it was adequately powered where the earlier literature was not, and it was conducted in the population where the hypothesis had been most enthusiastically advanced. A well-powered negative result in the best-studied indication is the single most informative datum in the behavioural literature on this compound.

Limitations. As with any negative trial, it does not exclude an effect in a different population, at a different amount, or over a different duration — and, given the open question about delivery, it does not cleanly distinguish absence of effect from absence of exposure ^[4].

The wider psychiatric literature

Meta-analytic position. A 2026 meta-analysis of clinical trials asked whether intranasal oxytocin reduces symptoms of mental disorders across conditions ^[6], and a separate systematic review and meta-analysis examined its effect on social interaction specifically in adults and children with autism spectrum disorders ^[7].

How to read pooled results in this field. Meta-analysis pools studies that are mostly small, mostly crossover, and mostly conducted before preregistration became usual — a combination that inflates apparent effects rather than cancelling them. Where pooled results and a large well-powered trial disagree, the trial is the better guide.

Placebo response as a finding in its own right

Design and result as reported. A randomised controlled trial in autism incorporated a placebo lead-in phase, and analysis of that phase characterised the magnitude of placebo response directly ^[8]. Predictors of placebo response in oxytocin autism trials have also been analysed.

Why it belongs here. Social-behaviour outcomes in children are rated by caregivers and clinicians who hope for improvement, in a condition with fluctuating presentation. A large placebo response is the expected consequence, and it is sufficient on its own to account for the positive findings of small uncontrolled or underpowered studies.

The obstetric evidence

Design and result as reported. An individual participant data meta-analysis has examined the effectiveness of oxytocin for preventing postpartum haemorrhage ^[9] — the highest tier of synthesis available, since it reanalyses the original participant-level records rather than published summaries.

Scope. This evidence concerns intravenous and intramuscular administration of a licensed product by clinicians at delivery. It says nothing about any other route, any other setting, or any other material, and it is the part of this compound's record that supports its approvals.

Preclinical Research on Oxytocin

Animal research

The animal work most relevant to the disputed question is not about oxytocin's effects but about whether an intranasally applied neurohypophysial peptide reaches the brain at all.

Intranasal vasopressin in rats. Intranasal application of vasopressin, oxytocin's close structural relative, failed to elicit changes in brain immediate early gene expression, in neural activity, or in behavioural performance ^[5].

What it establishes. In a species where the brain can be examined directly after administration, the expected central signature of intranasal delivery was absent. That is one peptide in one species and does not settle the question for oxytocin in humans. It does mean the assumption of central delivery requires evidence rather than convention, which is the argument the 2016 critique makes at greater length ^[4].

Findings described in this section were observed in rats. Nothing in them establishes anything about humans.

Current Research Status

Status as of September 22, 2026. This block is rendered from maintained fields, not from prose, so it cannot go stale in one place and stay current in another.

Oxytocin vs Related Compounds

Against vasopressin

The two neurohypophysial hormones differ at two of nine positions and cross-react at each other's receptors ^[1]. Any account attributing an observed effect specifically to oxytocin receptor activation has to contend with V1a activity, and most behavioural studies do not measure it.

Against carbetocin and other analogues

Longer-acting oxytocin analogues have been developed for obstetric use and are compared against oxytocin in the postpartum haemorrhage literature. They are distinct substances with distinct products and licences.

Against the other hypothalamic peptides here

Kisspeptin-54 and gonadorelin act on the reproductive axis through the pituitary gonadotropes. Oxytocin is released from the posterior pituitary and acts on peripheral target tissues directly. They share an anatomical neighbourhood and nothing else.

Against VIP

VIP is the other endogenous peptide in this library with approved-product history and a large investigational literature that has not matched it. The structural parallel is worth noting: in both cases a well-characterised endogenous molecule with a defined receptor has proved difficult to turn into a treatment outside its original physiological role.

No comparison of effect between these compounds is made on this page.

Chemical & Molecular Characteristics

Oxytocin is a cyclic nonapeptide of molecular formula C43H66N12O12S2 and average mass 1007.2 g/mol, under PubChem compound identifier 439302 and CAS registry number 50-56-6.

The disulphide bond is the molecule. The ring closed between cysteine 1 and cysteine 6 is what gives the peptide its shape and its activity. Reduction opens the ring and abolishes activity, and the reduced linear form differs from the intact peptide by only two daltons — far too little to distinguish reliably on an intact-mass measurement of a 1007-dalton species. This is the central analytical point about the compound: mass confirms composition, not the bond that makes it a hormone.

Disulphide scrambling, not only reduction. Under some conditions a cyclic peptide with a single disulphide can form intermolecular dimers and higher species of identical elemental composition per unit. These differ in mass by whole multiples and are detectable if looked for, and they are a recognised impurity class in the manufacture of peptides of this type.

The C-terminal amide is required. Hydrolysis to the free acid costs one dalton and abolishes activity. Two of the molecule's three critical structural features are therefore invisible to routine mass spectrometry.

One tyrosine, and no tryptophan. The single tyrosine provides modest absorbance near 275 nm, enough for quantification but weaker than a tryptophan-containing peptide would give. It is also a site of oxidation.

Historical note with a practical edge. Oxytocin was among the first peptide hormones to be chemically synthesised, and the field of peptide synthesis grew from that work. One consequence is that the impurity profile of synthetic oxytocin is better characterised, in the pharmacopoeial literature, than that of almost any other peptide — which is a reason to compare a certificate of analysis against a pharmacopoeial monograph rather than against a bare mass figure.

Frequently Asked Questions

Scientific References

1. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation Physiological reviews; 2001. PMID 11274341 doi:10.1152/physrev.2001.81.2.629
2. Sikich L, Kolevzon A, King BH, et al.. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder The New England journal of medicine; 2021. PMID 34644471 doi:10.1056/NEJMoa2103583
3. Spanos M, Chandrasekhar T, Kim SJ, et al.. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B) Contemporary clinical trials; 2020. PMID 32777383 doi:10.1016/j.cct.2020.106103
4. Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions Biological psychiatry; 2016. PMID 26049207 doi:10.1016/j.biopsych.2015.05.003
5. Ludwig M, Tobin VA, Callahan MF, et al.. Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats Journal of neuroendocrinology; 2013. PMID 23656518 doi:10.1111/jne.12046
6. Bonnieux J, Gumuchian ST, Harboun A, et al.. Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials Neuroscience and biobehavioral reviews; 2026. PMID 42134427 doi:10.1016/j.neubiorev.2026.106749
7. Fang G, Pan W, Li G, et al.. The Effect of Intranasal Oxytocin on Social Interaction in Adults and Children With Autism Spectrum Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials Alpha psychiatry; 2026. PMID 42694606 doi:10.31083/AP45322
8. Boulton KA, Thapa R, Song YJ, et al.. Evaluating placebo responses to intranasal oxytocin in autism: findings from the placebo lead-in phase of a randomised controlled trial Journal of child psychology and psychiatry, and allied disciplines; 2026. PMID 41550040 doi:10.1111/jcpp.70116
9. Flanagan M, Rattan A, Au LS, et al.. The Effectiveness of Oxytocin for Preventing Postpartum Haemorrhage: An Individual Participant Data Meta-Analysis BJOG : an international journal of obstetrics and gynaecology; 2026. PMID 40665776 doi:10.1111/1471-0528.18279

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.